Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Zoetis reported strong financial results in the second quarter of 2024, showcasing a robust operational growth across various segments and products.</li><li>Revenue increased by 11% operationally, while adjusted net income saw a significant operational growth of 18%.</li><li>The well-balanced growth was evident with a 12% increase in the U.S. and a 10% operational rise internationally, demonstrating the company's effective market strategies and innovative product offerings.</li></ul>

Zoetis reported strong financial results in the second quarter of 2024, showcasing a robust operational growth across various segments and products.Revenue increased by 11% operationally, while adjusted net income saw a significant operational growth of 18%.The well-balanced growth was evident with a 12% increase in the U.S. and a 10% operational rise internationally, demonstrating the company's effective market strategies and innovative product offerings.

Zoetis Inc.: Enhanced Direct-to-Consumer Marketing and ROI Focus Driving Our Optimism! - Major Drivers

<ul><li>Zoetis Inc., renowned for its commitment to innovation within the animal health market, came forward with outstanding first quarter results for 2024.</li><li>Steady demand for the company's products and focused strategies were key factors contributing to the growth.</li><li>Zoetis delivered 12% operational revenue growth and a 15% operational increase in adjusted net income.</li></ul>

Zoetis Inc., renowned for its commitment to innovation within the animal health market, came forward with outstanding first quarter results for 2024.Steady demand for the company's products and focused strategies were key factors contributing to the growth.Zoetis delivered 12% operational revenue growth and a 15% operational increase in adjusted net income.

Zoetis Inc.: These Are The 6 Fundamental Factors Driving Growth In 2024 & Beyond! - Financial Forecasts

<ul><li>Zoetis, a leading company in animal health, reported strong results for the full year with an operational revenue growth of 7% which was driven by the success of their diverse portfolio, innovation and the commitment of their colleagues.</li><li>Their products designed for pain relief in osteoarthritis contributed towards a 6% growth in the U.S. sector and 9% operational growth internationally.</li><li>The companion animal portfolio showed an operational growth increasing by 8%, while the livestock portfolio also witnessed improvements, growing by 6%.</li></ul>

Zoetis, a leading company in animal health, reported strong results for the full year with an operational revenue growth of 7% which was driven by the success of their diverse portfolio, innovation and the commitment of their colleagues.Their products designed for pain relief in osteoarthritis contributed towards a 6% growth in the U.S. sector and 9% operational growth internationally.The companion animal portfolio showed an operational growth increasing by 8%, while the livestock portfolio also witnessed improvements, growing by 6%.

Zoetis Inc: Librela & Other Factors Contributing To Its Competitive Edge! - Financial Forecasts

Fundamental Principles of the Stock Market, From 0 to 1 in the Stock Market

From 0 to 1 in the Stock Market

Fundamental Principles of the Stock Market

Fundamental principles of the stock market, earnings reviews and research. My name is Giuliano Mana, I’m 23 years old. I have a B.A Degree in Finance and I’m a Master’s candidate at Brandeis IBS. I’ve been thoroughly going over huge amounts of reading material regarding the stock market and hope to transmit some insights here.

<ul><li>Zoetis is the global leader in the animal health industry. It discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic products and services.</li><li>Zoetis counts with over 300 product lines, with 15 of them generating over 100M in annual sales.</li><li>The latter are called blockbusters, and the company holds</li></ul>

Zoetis is the global leader in the animal health industry. It discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic products and services.Zoetis counts with over 300 product lines, with 15 of them generating over 100M in annual sales.The latter are called blockbusters, and the company holds

<ul><li>Honestly, I’m stunned I’m writing this. I did my research on Zoetis during June, July and August, and my conclusion seemed, funnily, conclusive.</li><li>My suspicion was that Zoetis was as close to being a truly durable company as possible.</li><li>Even though the object of this article does not claim otherwise, it does indeed reveal something I completely overlooked. My conclusion was ultimately drawn from the following:</li></ul>

Honestly, I’m stunned I’m writing this. I did my research on Zoetis during June, July and August, and my conclusion seemed, funnily, conclusive.My suspicion was that Zoetis was as close to being a truly durable company as possible.Even though the object of this article does not claim otherwise, it does indeed reveal something I completely overlooked. My conclusion was ultimately drawn from the following:

Under The Lens of Disruption: Zoetis - VetKiosk

United States

Zoetis Inc discovers, develops, manufactures and commercializes animal health medicines and vaccines, with a focus on both livestock and companion animals.  The Companies products are sold in North America, Europe, Africa, Asia, Australia and Latin America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zoetis Inc (ZTS US)

Zoetis Inc.: Enhanced Direct-to-Consumer Marketing and ROI Focus Driving Our Optimism! - Major Drivers

Zoetis reported strong financial results in the second quarter of 2024, showcasing a robust operational growth across various segments and...

Baptista Research

Zoetis Inc.: These Are The 6 Fundamental Factors Driving Growth In 2024 & Beyond! - Financial Forecasts

Zoetis Inc., renowned for its commitment to innovation within the animal health market, came forward with outstanding first quarter results for...

Baptista Research

Zoetis Inc: Librela & Other Factors Contributing To Its Competitive Edge! - Financial Forecasts

Zoetis, a leading company in animal health, reported strong results for the full year with an operational revenue growth of 7% which was driven by...

Baptista Research

Under The Lens of Disruption: Zoetis - VetKiosk

Honestly, I’m stunned I’m writing this. I did my research on Zoetis during June, July and August, and my conclusion seemed, funnily, conclusive.

From 0 to 1 in the Stock Market

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Zoetis Inc.: Enhanced Direct-to-Consumer Marketing and ROI Focus Driving Our Optimism! - Major Drivers

Zoetis reported strong financial results in the second quarter of 2024, showcasing a robust operational growth across various segments and...

Baptista Research

Zoetis Inc.: These Are The 6 Fundamental Factors Driving Growth In 2024 & Beyond! - Financial Forecasts

Zoetis Inc., renowned for its commitment to innovation within the animal health market, came forward with outstanding first quarter results for...

Baptista Research

Zoetis Inc: Librela & Other Factors Contributing To Its Competitive Edge! - Financial Forecasts

Zoetis, a leading company in animal health, reported strong results for the full year with an operational revenue growth of 7% which was driven by...

Baptista Research

Zoetis One-Pager

Zoetis is the global leader in the animal health industry. It discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic...

From 0 to 1 in the Stock Market

Under The Lens of Disruption: Zoetis - VetKiosk

Honestly, I’m stunned I’m writing this. I did my research on Zoetis during June, July and August, and my conclusion seemed, funnily, conclusive.

From 0 to 1 in the Stock Market